This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
ChanTest announces development of newly validated and re-engineered cells to support a critical element of the drug discovery process for the biopharmaceutical industry.
Cleveland, Ohio (PRWEB) July 10, 2014
Understanding the need for better quality and higher consistency in ion channel-expressing cell lines, and the gap that currently exists in this area, ChanTest has recently developed new cells that expand its industry-leading portfolio of validated ion channel and GPCR cell lines. ChanTests research focuses on ion channel-expressing cell lines, as ion channels control many critical physiological functions throughout the body. Being able to control this activity creates the potential to treat a variety of human diseases.
ChanTest has validated these cells using their automated electrophysiology and fluorescent plate reader systems.
Because of their control over many critical physiological functions, ion channels are one of the most important categories of drug targets in the pharmaceutical industry. With the growing need to test the safety and efficiency of new drugs, the importance of an organized library of cell lines is critical.
ChanTests cell and molecular biology group has developed several new or improved recombinant cells expressing ligand-gated ion channels. Two of these new products, CTN6117 (stably transfected) and CTN7117 (transiently transfected), consist of ionotropic serotonergic (5-HT3A) receptors expressed in HEK293 cells. 5-HT3A is a therapeutic target in nausea and irritable bowel syndrome. Also, new cell lines have been developed that stably express nicotinic acetylcholine receptor subtypes in CHO cells. These include 345 (CT6024) and 24 (CT6023), which are important therapeutic targets in several neurological indications, and join previously developed nicotinic 7 (CT6201) and 34 (CT6021) subtype-expressing cell lines in our catalog. ChanTest has engineered all cells for optimal performance in automated patch clamp and FLIPR high throughput screening systems.
In combination with automated medium- to high-throughput functional assays, ChanTest can help organizations rapidly profile compounds across a range of ion channels. ChanTest can also help to construct and validate other cell lines in a timely and cost effective manner.
For a complete list of available cell lines, visit: http://www.chantest.com/reagents/ion-channel/cell-lines.
About ChanTest® The Ion Channel Expert
ChanTests mission is to serve the drug discovery and development needs of customers worldwide. Since its start in 1998, the Contract Research Organization has tested compounds for more than 300 global pharmaceutical and biotechnology companies. ChanTest also partners with these companies to accelerate the drug development process for the release of better, safer drugs. ChanTest offers ion channel and GPCR cell reagents, ion channel screening/profiling services, and cardiac safety services. The companys library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercial library available today.
Because of ChanTests influential role, along with the companys uncompromising commitment to quality, an independent survey has named ChanTest the most trusted and most used fee-for-service provider since 2006. ChanTest is based in Cleveland, Ohio.
Visit http://www.chantest.com to learn more about ChanTest.
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12003806.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.